In part this is due to the fact that it remains controversial whether tumor or patient characteristics are more relevant in the context of TGF-β inhibition, that is, what are the relative contributions of autocrine or paracrine activities of TGF-β as opposed to TGF-β effects on the host in the pathogenesis of glioblastoma. The gene discussed is TGFB1; the disease is glioblastoma.